Zhao Enmin, Han Demin, Yu Zhenkun, Fan Erzhong, Li Ying, Zhou Zijie
Department of Otolaryngology-Head and Neck Surgery, the First Hospital of Peking University, Beijing 100034.
Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2002 Nov;16(11):599-602.
The aim of the present study was to evaluate whether the expression of uPA parameters might be of clinical value in squamous cell carcinoma of human larynx as a tumor/biologically defined risk factor.
In a consecutive series of 127 patients resected for primary squamous cell carcinoma of human larynx, the expression of uPA and plasminogen activator inhibitors (PAI) type-1, type-2 was determined immunohistochemically. The results were classified as positive and negative. Patients were followed-up prospectively for a median of 41 months(rang 6 to 84 months). Overall survival were analyzed according to Kaplan-Meier and log-rank statistics, the prognostic relevance of uPA, PAI-1, PAI-2 and conventional prognostic factors were analyzed by Cox analyses.
These revealed a high significant inverse correlation of uPA positive expression survival time(P = 0.006); and patients with PAI-2 positive expression had a significantly longer survival time than those with PAI-2 negative expression(P = 0.009); in different clinicopathological parameters subgroups uPA, PAI-2 added significant survival information, whereas PAI-1 positive expression did not associate with prognoses. Patients with uPA-positive/PAI-2-negative expression had the poorest prognoses. Multivariate analysis revealed that four independent prognostic factors for overall survival time were uPA, PAI-2, lymph node metastasis and differentiation of tumor, P = 0.0002, 0.0001, 0.0117, 0.0436 respectively, relative risk and 95% confidence interval were 1.99 (1.39 to 2.85) 0.36 (0.212 to 0.609), 2.36 (1.21 to 4.61) 1.51 (1.01 to 2.25) respectively.
We conclude that uPA and PAI-2 are new independent and strong biologically prognostic factors, uPA positive expression may be a powerful aid in evaluating metastatic potential and high risk patients in early stage of human larynx carcinoma.
本研究旨在评估作为肿瘤/生物学定义的危险因素,尿激酶型纤溶酶原激活物(uPA)参数的表达在人喉鳞状细胞癌中是否具有临床价值。
在连续127例因原发性人喉鳞状细胞癌而接受手术切除的患者中,采用免疫组织化学方法测定uPA及纤溶酶原激活物抑制剂-1(PAI-1)、纤溶酶原激活物抑制剂-2(PAI-2)的表达。结果分为阳性和阴性。对患者进行前瞻性随访,中位随访时间为41个月(范围6至84个月)。根据Kaplan-Meier法和对数秩检验分析总生存期,通过Cox分析评估uPA、PAI-1、PAI-2及传统预后因素的预后相关性。
这些结果显示uPA阳性表达与生存时间呈高度显著负相关(P = 0.006);PAI-2阳性表达的患者生存时间显著长于PAI-2阴性表达的患者(P = 0.009);在不同临床病理参数亚组中,uPA、PAI-2增加了显著的生存信息,而PAI-1阳性表达与预后无关。uPA阳性/PAI-2阴性表达的患者预后最差。多因素分析显示,总生存时间的四个独立预后因素为uPA、PAI-2、淋巴结转移和肿瘤分化,P值分别为0.0002、0.0001、0.0117、0.0436,相对危险度及95%可信区间分别为1.99(1.39至2.85)、0.36(0.212至0.609)、2.36(1.21至4.61)、1.51(1.01至2.25)。
我们得出结论,uPA和PAI-2是新的独立且强大的生物学预后因素,uPA阳性表达可能有助于评估人喉癌早期的转移潜能和高危患者。